Provider review
DudeMeds review: it explains why compounded drugs are risky, then calls its compounded GLP-1 a generic
DudeMeds has the best explanation of compounding risk we have read on a seller's own site. It sits on the testosterone page. It is accurate, and it is the reason the company gives for using commercial testosterone instead. Then move to the weight-loss side, where the same company sells semaglutide at a fraction of the brand price and describes it as an "Ozempic/Wegovy generic" and an "FDA-approved medication". There is no generic semaglutide in the United States. The word compounded appears on one page of this site, and it is not either of the GLP-1 ones.
Partner link — we may earn a commission. How we’re paid
Visit DudeMedsOf DudeMeds’s 2 dated product claims documented below, 0 are consistent with the cited evidence. Among the dated prices documented below, the lowest listed upfront charge is $295 for 30 days (Compounded semaglutide, paying month to month). A matching claim does not mean the compounded product was tested or FDA-approved.
Explains compounding risk better than any seller here, on the one product line where it doesn't apply. Then calls its compounded GLP-1 a generic.
Worth trusting if
- You want testosterone and want the commercial product rather than a compounded one
- You want to see the price before answering health questions, because here you do
- You want the brand drug and would rather see it priced openly beside the alternatives
Be skeptical if
- You need to know whether your medication is compounded, because the weight-loss pages never say
- You read "generic" as meaning an approved equivalent, because no such thing exists for these molecules
- You want to look a price up later, because none of them are text
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at DudeMeds
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — $295 a month to pay monthly; the advertised $175 needs a six-month commitment.
- Compounded tirzepatide injection — $433 a month to pay monthly; $249 on a three-month prepay.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 2 products reviewed here. The evidence concerns the molecule, not DudeMeds's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from DudeMeds’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim reaches past the trials
“Semaglutide has been shown to reduce body weight by 10-15% over a 68-week period in individuals with obesity, according to clinical trials. Semaglutide (Ozempic/Wegovy generic): What to expect. Semaglutide effectively aids in weight loss by reducing appetite and improving insulin sensitivity. Expect gradual but consistent weight loss with regular use.”
Read on the DudeMeds site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults titrated to semaglutide 2.4 mg weekly, reporting a mean reduction of about 15% against about 2% on placebo. DudeMeds gives the right trial and the right duration, and states a range rather than a single figure.
The weight-loss arithmetic is fine — 10 to 15% over 68 weeks is a fair reading of STEP 1, and quoting a range rather than the best number is more honest than most of this market manages. What fails is the description of the product. There is no generic semaglutide in the United States: the molecule is on patent and no approved generic exists, so a compounded preparation cannot be one. The site's weight-loss page compounds that by calling semaglutide "an FDA-approved medication", when the approval belongs to Ozempic and Wegovy, which DudeMeds sells separately on the same site for roughly nine times the price. A reader could finish this page believing they are buying an approved drug at a discount, and they are not.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim reaches past the trials
“Tirzepatide has been shown to reduce body weight by up to 22.5% in clinical trials, offering groundbreaking results in obesity treatment. Tirzepatide (Zepbound/Mounjaro generic): What to expect. Tirzepatide provides powerful weight loss support by targeting multiple metabolic pathways. Expect consistent results with regular use.”
Read on the DudeMeds site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly. It reported about 20.9% at the top dose on one analysis and 22.5% on a second — so the figure DudeMeds quotes is real, and it is the more favorable of the two.
The 22.5% survives checking, which is worth saying because it looks at first like an inflated number. SURMOUNT-1 reported two analyses at the top dose and 22.5% is the second of them — the page picks the better one and does not say so, which is a small thing rather than a false one. The problem is the same as on the semaglutide page and it is not small. Tirzepatide has no generic in the United States, so nothing sold here can be one, and the FDA approval the site's weight-loss page claims for tirzepatide belongs to Zepbound and Mounjaro. Those two are also sold on this site, priced separately, at several times what this product costs.2
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named for either side of the business. The homepage describes DudeMeds as an online doctors office plus pharmacy and says medication ships within about 48 hours of approval, without identifying a facility, an address or a license number. The TRT pages go furthest, committing to commercial testosterone cypionate rather than a compounded preparation and explaining why — which tells you what kind of product arrives without telling you who dispensed it. The weight-loss pages make no equivalent statement in either direction: they never say the medication is compounded, and they never say it is not. Checked across eight pages in September 2026.
Read on the DudeMeds site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published for any product. On testosterone DudeMeds offers something in place of test data that is arguably better: it commits to a commercially manufactured product and explains what that buys you over a compounded one, including a longer beyond-use date. Nothing comparable appears on the weight-loss side, where the product type is never stated. Its LegitScript seal links to the checker keyed to this domain and the checker resolves, which proves a certificate was issued rather than anything about what ships. One quieter point: every weight-loss price is drawn inside an image, so nothing about the commercial terms can be searched or archived either.
Read on the DudeMeds site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
DudeMeds says no face-to-face visit is required "in most states", which is its own hedge and the closest thing to a coverage statement on the site. It publishes no state list and no exclusions on the weight-loss pages, the catalog or the legal section. The TRT route does require a video visit with a doctor licensed in your state, so availability there depends on where you live. Checked September 2026.
Read the full licensing claim
The operating company is named — DudeMeds LLC, in the privacy policy — which is more than most sellers here manage. No registered address, state of incorporation, medical director or individual prescriber is published.
Read on the DudeMeds site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
We did this ourselves
What happens when you sign up with DudeMeds
We went through DudeMeds’s signup ourselves in September 2026: the steps, when a price first appears, and what it asks you for. We stopped at checkout, so nothing here is a prescription or a medical result.
- What type of patient are you? — new patient or refill
- Injection or oral
- Select the medication: semaglutide, tirzepatide, or a brand name
- "What's your Commitment Level?" — the plan cards, with the prices
- For refills, a dose is chosen first: low, medium or high
- Prices come early, before any health question, which is the opposite of most sellers here.
- Every price is an image. No screen shows a dollar figure as text.
- The word compounded appears on no screen of the weight-loss signup.
- Brand pens are offered on the same screens at roughly nine times the price of the cheap products.
- The cheapest new-patient plan is $175 a month; the site's own headline says prices from $149.
- On the tirzepatide refill screen, the medium-dose card shows a vial labeled Se rather than Tz.
- The refill brand page still reads "NEW PATIENT MONTHS 1 + 2 + 3".
DudeMeds support
Assessment
What holds up, and what does not
- Its testosterone pages explain why commercial product beats compounded, accurately and in detail.
- It commits to commercial testosterone cypionate rather than a compounded preparation, and says so plainly.
- The semaglutide figure — 10 to 15% over 68 weeks — matches STEP 1 and is given as a range.
Show 5 more
- The tirzepatide figure of 22.5% is a real number from SURMOUNT-1, not an invented one.
- Brand-name Ozempic, Wegovy, Mounjaro and Zepbound are sold and priced openly alongside the cheaper options.
- Prices appear before any health question rather than after a home address.
- The operating company is named in the privacy policy, which most sellers here avoid.
- Its LegitScript certification is real and keyed to this domain.
- It calls its semaglutide an "Ozempic/Wegovy generic" and no generic semaglutide exists in the United States.
- It calls its tirzepatide a "Zepbound/Mounjaro generic", and the same is true of that molecule.
- The weight-loss landing page describes both semaglutide and tirzepatide as FDA-approved, which the compounded product is not.
Show 5 more
- The word compounded appears on one page of the site, and it is the testosterone one.
- The medication pages borrow the section headings of an approved drug's label for a product with none.
- No pharmacy is named for either the weight-loss or the testosterone side.
- No clinician, medical director or prescriber is named anywhere.
- Every weight-loss price is drawn inside an image and cannot be searched or archived.
Verdict
The bottom line
Read the testosterone FAQ, then read the semaglutide page, and notice that the same company wrote both. The first explains exactly why a compounded drug is a different proposition from an approved one; the second sells a compounded drug using the words generic and FDA-approved. Nothing here misrepresents what the molecules do. The trial figures check out. What is misrepresented is what you would be buying. Ask DudeMeds directly whether the medication is compounded and which pharmacy makes it, and get the answer in writing before you pay.
Opens DudeMeds' website. A link is not a recommendation to take anything.
Two pages, one company
From DudeMeds' testosterone page, answering its own question "Why does DudeMeds only use Commercial injectable Testosterone and not compounded?":
"Commercial testosterone is FDA-approved, produced in sterile environments, and rigorously tested… In contrast, compounded testosterone lacks FDA oversight, leading to variability in potency, quality, and sterility. It also carries a higher risk of contamination…"
That is correct, and it is better than almost anything else written on the subject by a seller.
From its semaglutide page, on the same site:
"Semaglutide (Ozempic/Wegovy generic): What to expect"
And from its weight-loss page:
"Semaglutide is an FDA-approved medication shown to significantly aid weight loss…"
Full analysis — 5 more sectionsThere is no generic semaglutide · How we know which one is being sold · The trial numbers are fine · A label that isn't one · What to ask
There is no generic semaglutide
Not in the United States. Semaglutide and tirzepatide are both on patent, and no approved generic exists for either molecule.
A generic is an FDA-approved copy demonstrated to be bioequivalent to the original. A compounded preparation is made to order by a pharmacy, is not FDA-approved, and has not been evaluated by the FDA for safety, effectiveness or quality.
They are close to opposites. The testosterone page says so.
How we know which one is being sold
Not by inference. By DudeMeds' own pricing, on the pages you click through to buy:
| Product | Price |
|---|---|
| Ozempic, Wegovy | $1,585/mo |
| Mounjaro, Zepbound | $1,350/mo |
| "Semaglutide" | $175–$295/mo |
| "Tirzepatide" | $249–$433/mo |
A seller offering Wegovy at $1,585 and semaglutide at $175 is not offering the same product twice.
Then there is the word itself. Across eight pages — both medication pages, the weight-loss landing page, the medication index and every plan screen — "compound" appears once, on the testosterone page.
The trial numbers are fine
This is worth stating clearly, because the failure here is narrow and it would be unfair to widen it.
Semaglutide: "10-15% over a 68-week period". STEP 1 randomized 1,961 adults and reported about 15% at 68 weeks. 1 Right trial, right duration, and a range rather than the single best figure.
Tirzepatide: "up to 22.5%". SURMOUNT-1 reported roughly 20.9% at the top dose on one analysis and 22.5% on another. 2 The page uses the more favorable one without saying which — a small thing, and not a fabricated number.
So DudeMeds is not exaggerating what these drugs do. It is misdescribing what it sells.
A label that isn't one
Both medication pages are laid out under the headings of an FDA package insert — Prescribing Information, Indications and Usage, Clinical Pharmacology, Contraindications, Warnings and Precautions.
The text under them is short and broadly accurate. But that structure belongs to a drug with an approved label, and a compounded preparation does not have one.
What to ask
Two questions, and get them answered in writing:
1. Is the medication compounded? The pages never say. The price says yes. 2. Which pharmacy makes it? No facility is named for either product line.
The company that wrote the testosterone FAQ knows why both questions matter.
Questions
Frequently asked questions
Is DudeMeds selling real Ozempic?
Both are on offer and the prices separate them. Ozempic and Wegovy are listed at $1,585 a month and Mounjaro and Zepbound at $1,350, as their own products. The cheaper semaglutide and tirzepatide, from $175 and $249, are a different thing — compounded, though the pages selling them never use the word.
Is there such a thing as generic semaglutide?
Not in the United States. Semaglutide and tirzepatide are both on patent and neither has an approved generic. A generic is an FDA-approved copy proven bioequivalent to the original; a compounded preparation is made to order by a pharmacy and has not been evaluated by the FDA at all.
Are the weight-loss figures accurate?
Yes. The semaglutide claim of 10 to 15% over 68 weeks matches STEP 1, and quoting a range is more honest than picking the best number. The tirzepatide claim of up to 22.5% is a real SURMOUNT-1 result, though it is the more favorable of two analyses and the page doesn't say so.
What does DudeMeds say about compounded drugs?
On testosterone, a great deal, and it is accurate — compounded product lacks FDA oversight, varies in potency and sterility, and carries a higher contamination risk. That is the reason it gives for using commercial testosterone instead. The GLP-1 pages make no equivalent statement in either direction.
Why can't I find the weight-loss prices by searching?
Because none of them are text. Every plan card is a picture with the price drawn into the artwork, so a search engine, a screen reader and a price tracker see an image and nothing more.
Glossary
Key terms
Show definitions
- Generic
- An FDA-approved copy of an approved drug, demonstrated to be bioequivalent to it. No generic semaglutide or tirzepatide exists in the United States — both molecules remain on patent.
- 503A
- A pharmacy that makes a drug to order for one named patient with a prescription. What it produces is not FDA-approved, and the FDA has not evaluated its safety, effectiveness or quality.
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021, reporting a mean reduction of about 15%.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg, published in the New England Journal of Medicine in 2022, reporting about 20.9% at the top dose on its primary analysis and 22.5% on a second.
Compare
Others selling what DudeMeds sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists DudeMeds is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off DudeMeds's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults, mean weight reduction of about 15% reported at 68 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults, about 20.9% mean reduction at the top dose on the treatment-regimen analysis and 22.5% on the efficacy analysis, at 72 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.